Contract Research Organizations (“CROs”) and Contract Development and Manufacturing Organizations (“CDMOs”) are a critical backbone in the life sciences ecosystem, delivering research, development and manufacturing capabilities that innovators rely on. They accelerate timelines, reduce capital burdens for drug innovators, and bring specialized expertise that can make — or break — the path from lab to patient. But when client drug pipelines stall, regulatory requirements shift or markets tighten, these organizations can be left exposed. Several critical areas stand out for CRO and CDMO leaders and investors in 2025.
Read the full article: Five Priorities for Life Sciences Service Providers //
Source: https://www.lexology.com/library/detail.aspx?g=ad54ce4f-9879-4f6d-a754-89365bab8bb6